Analysts Set Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) PT at $61.40

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) has been assigned a consensus rating of "Buy" from the eight research firms that are covering the firm, MarketBeat reports. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $59.20.

Several analysts recently weighed in on the company. Cantor Fitzgerald restated an "overweight" rating on shares of Arcturus Therapeutics in a report on Friday, March 7th. Canaccord Genuity Group reduced their price objective on shares of Arcturus Therapeutics from $74.00 to $68.00 and set a "buy" rating for the company in a research note on Monday. HC Wainwright decreased their price objective on Arcturus Therapeutics from $63.00 to $60.00 and set a "buy" rating for the company in a research note on Friday, March 7th. Wells Fargo & Company reduced their target price on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an "overweight" rating for the company in a report on Friday, March 7th. Finally, BTIG Research set a $48.00 price target on shares of Arcturus Therapeutics and gave the company a "buy" rating in a report on Monday.

Hedge Funds Weigh In On Arcturus Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Franklin Resources Inc. increased its stake in Arcturus Therapeutics by 54.6% during the 3rd quarter. Franklin Resources Inc. now owns 103,936 shares of the biotechnology company's stock valued at $2,412,000 after purchasing an additional 36,714 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of Arcturus Therapeutics by 45.6% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,275,715 shares of the biotechnology company's stock valued at $52,819,000 after buying an additional 712,650 shares during the last quarter. Empire Life Investments Inc. grew its holdings in shares of Arcturus Therapeutics by 85.5% during the fourth quarter. Empire Life Investments Inc. now owns 279,463 shares of the biotechnology company's stock valued at $4,742,000 after buying an additional 128,771 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its position in shares of Arcturus Therapeutics by 139.7% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 82,057 shares of the biotechnology company's stock valued at $1,393,000 after acquiring an additional 47,824 shares during the period. Finally, Spire Wealth Management raised its stake in Arcturus Therapeutics by 393.3% in the 4th quarter. Spire Wealth Management now owns 13,478 shares of the biotechnology company's stock worth $229,000 after acquiring an additional 10,746 shares during the last quarter. 94.54% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Arcturus Therapeutics Stock Performance

Shares of ARCT traded down $0.36 during mid-day trading on Monday, hitting $13.90. 317,895 shares of the company traded hands, compared to its average volume of 426,387. The stock has a 50-day moving average price of $16.78 and a two-hundred day moving average price of $18.41. The stock has a market cap of $376.97 million, a price-to-earnings ratio of -6.26 and a beta of 2.96. Arcturus Therapeutics has a 1 year low of $12.75 and a 1 year high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last released its earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.78). The business had revenue of $22.77 million for the quarter, compared to analysts' expectations of $44.64 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. On average, analysts forecast that Arcturus Therapeutics will post -2.22 EPS for the current year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.